Surgically Targeted Radiation Therapy (STaRT) for patients with operable brain tumors

Right Treatment. Right Time. Right Place.

GammaTile Therapy is a Surgically Targeted Radiation Therapy (STaRT) that provides immediate, dose-intense treatment at the completion of resection. By getting a head STaRT on fighting the tumor, resection plus GammaTile Therapy can extend local recurrence-free survival with minimal complications, reduced patient burden, and assured compliance.[1]

Elevating Outcomes With Optimized Dosimetry

GammaTile Therapy vs Intensity-Modulated Radiation Therapy (IMRT)

GammaTile is designed with uniform radiation-source spacing to ensure an even dose distribution. The favorable depth-dose profile optimizes local tumor control.[2]

The colors indicate the radiation location and intensity from the 2 types of treatment. Blue-green indicates lower radiation levels. Red indicates higher levels. The extracranial dose is likely lower than shown, as the planning system did not utilize inhomogeneity corrections.

Proven Efficacy

LOCAL CONTROL: RECURRENT BRAIN METASTASES AND RECURRENT MENINGIOMAS

GammaTile Therapy significantly improves local control vs the previous standard-of-care treatment in patients with recurrent brain metastases and recurrent meningiomas.[3,4]

RECURRENT BRAIN METASTASES[3,+]

Recurrent Brain Metastases GT Medical Technologies

RECURRENT MENINGIOMAS[4,+]

Recurrent Meningiomas GT Medical Technologies
†Results compared different treatments within the same patient population.

OVERALL SURVIVAL: RECURRENT GLIOBLASTOMA [5,6]

GammaTile Therapy demonstrates a potential for improved overall survival when comparing the effectiveness of surgery plus GammaTile Therapy to other treatment modalities across different clinical studies in patients with recurrent glioblastoma (GBM).

Recurrent Glioblastoma GT Medical Technologies

Advancing Safety

Designed with the brain’s delicate environment in mind to limit radiation changes in healthy tissue[10]

RADIATION-RELATED ADVERSE EVENTS

How It Works. An Eloquent Solution.

GammaTile Therapy targets tumor cells while preserving brain tissue. Surgically guided treatment of the local radiation dose to the operative bed optimizes the therapeutic margin while minimizing complications.[1]
Structural offset of the radiation source from the brain tissue prevents harmful direct seed-to-tissue contact and enables intraoperative adjustment.

Achieve local control with optimized dosimetry

  • 50% of the therapeutic dose is delivered within the first 10 days after surgery, which helps prevent residual tumor cells from replicating.[14]
  • 88% of the therapeutic dose is delivered within 30 days, with more than 95% of the dose delivered by 6 weeks.[14]
  • A favorable depth-dose profile optimizes local tumor control.[2]

Cesium-131 Distribution and Intensity

Bioresorbable, conformable collagen tile preserves healthy tissue

• GammaTile uses a Cesium-131 radiation source, which has a half-life of 9.7 days[3]
• Favorable depth-dose profile optimizes local tumor control[15,16]
• Uniform radiation-source spacing ensures a predictable, therapeutic radiation dose
• Its design helps limit the radiation exposure to medical staff and caregivers[17]

Uniform Radiation Source,
Structurally Offset Design

2-cm height | 2-cm width | 4-mm thickness

GammaTile Therapy fills a significant void in delivering safe and effective surgically targeted radiation therapy for malignant brain cancer. Its ease of placement fits seamlessly into the operative workflow and gives neurosurgeons and radiation oncologists another potent tool to improve our patients’ outcomes.
Ryan Morton, MD, FAANS
Chief of Neurosurgery at Brooke Army Medical Center Director of Cerebrovascular and Endovascular Neurosurgery
GammaTile treatment for newly diagnosed brain tumors is a significant step forward for patients and an example of the benefits that focused neurosurgical research and clinical innovation can provide. The targeted radiation delivered by GammaTile will save lives and set the stage for further groundbreaking advances against brain tumors. At Mayfield, we are committed to that research and innovation and delighted to be colleagues with a distinguished roster of clinical providers.”
Vincent A DiNapoli, MD, PhD
Neurosurgeon at Mayfield Brain & Spine, Director of the Brain Tumor Center at The Jewish Hospital – Mercy Health
With GammaTiles, we can deliver a boost of radiation at an intensity that could not otherwise be delivered to the area to prevent the tumor from growing back. Because of the creators of GammaTiles, we have been able to help many of our patients by extending their survival and improving their quality of life.”
Clark C Chen, MD, PhD
Lyle A French Chair of Neurosurgery, Professor and Department Head, University of Minnesota Neurosurgery
There’s currently no other device that’s able to achieve what GammaTile has for our brain tumor patients. It’s the first device of its kind, and its ability to deliver safe and effective surgically targeted radiation is groundbreaking in the neuro-oncology community.”
Julian Bailes, MD
Chair of the Department of Neurosurgery at NorthShore University HealthSystem and Surgical Director of the NorthShore Neurological Institute
We are excited to offer GammaTile as an additional treatment option to brain tumor patients with difficult-to-treat disease. It is also convenient, by combining radiation and surgery into one procedure.”
Kimberly B Hoang, MD
Assistant Professor, Department of Neurosurgery, Emory University SOM, Winship Cancer Institute
We’re excited to offer GammaTile because we’re providing patients with an option for treatment when they may have otherwise never had one. It allows us to give patients a longer chance of survival and better quality of life without the need for continuous and potentially lengthy treatment options.”
David Jay McCracken, MD
Neurosurgical Oncology at Piedmont Healthcare and Co-Director of the Piedmont Brain Tumor Center – an MD Anderson Provider Network Clinic

Learn more about GammaTile Therapy

Visit our patient site to explore patient testimonials, webinars, publications, and more

REFERENCES

1. Nakaji P, Youssef E, Dardis C, Smith K, Pinnaduwage D, Brachman D. Surgically targeted radiation therapy: a prospective trial in 79 recurrent, previously irradiated intracranial neoplasms. Poster presented at: 2019 AANS Annual Scientific Meeting; April 2019; San Diego, CA.

2. Armpilia CI, Dale RG, Coles IP, Jones B, Antipas V. The determination of radiobiologically optimized half-lives for radionuclides used in permanent brachytherapy implants. Int J Radiat Oncol Biol Phys. 2003;55(2):378-385.

3. Nakaji P, Smith K, Youssef E, et al. Resection and surgically targeted radiation therapy for the treatment of larger recurrent or newly diagnosed brain metastasis: results from a prospective trial. Cureus. 12(11):1-12.

4. Rogers L, Nakaji P, Youssef E, et al. Resection and surgically targeted radiation therapy for initial salvage treatment of aggressive meningioma: results from a prospective trial. Presented at: CNS 2020 Virtual Meeting; September 30, 2020.

5. Brachman D, Nakaji P, Smith K, et al. Resection and Surgically Targeted Radiation Therapy for locally recurrent GBM. J Clin Oncol. 2021;39(15):abstr 2054.

6. Tsien C, Pugh S, Dicker AP, et al. Randomized phase II trial of re-irradiation and concurrent bevacizumab versus bevacizumab alone as treatment for recurrent glioblastoma (NRG Oncology/RTOG 1205): initial outcomes and RT plan quality report. Int J Radiat Oncol Biol Phys. 2019;105(1):S78.

7. Clarke J, Ennis M, Yung W, et al. Is surgery at progression a prognostic marker for improved 6-month progression-free survival or overall survival for patients with recurrent glioblastoma? Neuro-Oncology. 2011;13(10):1118-1124.

8. Stupp R, Wong E, Kanner A, et al. NovoTTF-100A versus physician’s choice chemotherapy in recurrent glioblastoma: a randomised phase III trial of a novel treatment modality. Euro J Cancer. 2012;48(14):2192-2202.

9. Shi W, Bryan M, Gilbert M, et al. Investigating the effect of reirradiation or systemic therapy in patients with glioblastoma after tumor progression: a secondary analysis of NRG Oncology/Radiation Therapy Oncology group trial 0525. Int J Radiat Oncol Biol Phys. 2018;100(1):38-44.

10. Brachman D, Youssef E, Dardis C, Smith K, Pinnaduwage D, Nakaji P. Surgically targeted radiation therapy: Safety profile of collagen tile brachytherapy in 79 recurrent, previously irradiated intracranial neoplasms on a prospective clinical trial. Brachytherapy. 2019;18(3):S35-S36.

11. Combs SE, Debus J, Schulz-Ertner D. Radiotheraputic alternatives for previously irradiated recurrent gliomas. BMC Cancer. 2007;7:167.

12. Wernicke AG, Smith AW, Taube S, et al. Cesium-131 brachytherapy for recurrent brain metastases: durable salvage treatment for previously irradiated metastatic disease. J Neurosurgery. 2017;126(4):1212-1219.

13. Magill ST, Lau D, Raleigh DR, Sneed PK, Fogh SE, McDermott MW. Surgical resection and interstitial iodine-125 brachytherapy for high-grade meningiomas: a 25-year series. Neurosurgery. 2017;80(3):409-416.

14. Brachman D, Youssef E, Dardis C, et al. Resection and permanent intracranial brachytherapy using modular, biocompatible cesium-131 implants: results in 20 recurrent, previously irradiated meningiomas. J Neurosurgery. 2019;131(6):1819-1828.

15. Pinnaduwage D, Youssef E, Sorensen S, et al. Dosimetric impact of radioisotope type on permanent brain seed implants. Medical Physics. 2017;44(6):3146.

16. Armpilia C, Dale R, Coles I, et al. The determination of radiobiologically optimized half-lives for radionuclides used in permanent brachytherapy implants. Int J Radiat Oncol Biol Phys. 2003;55(2):378-385.

17. Moss NS, Imber BS, Prasad K, et al. Permanent intracavitary Cs131 brachytherapy for previously-irradiated recurrent brain metastases: initial clinical and radiation safety experience. Neuro-Oncol Advances. 2020;2(suppl 2):ii14.

GammaTile® is indicated as a treatment for patients with newly diagnosed malignant intracranial neoplasms and patients with recurrent intracranial neoplasms. For full product and safety information, refer to the Instructions for Use.